Comparison · NCT02771977-e0aa922f
Drug-specific Alert vs Usual Care: Percentage of Patients With AKI Progression From Stage 2 to Stage 3
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Drug-specific Alert vs Usual Care: Percentage of Patients With AKI Progression From Stage 2 to Stage 3. Trial comparisons, record NCT02771977-e0aa922f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02771977-e0aa922f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0935 | 0.0827 | 0.106 | wilson | |
| Risk in group 2 | 0.103 | 0.0919 | 0.116 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00979 | -0.0264 | 0.00684 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.905 | 0.765 | 1.07 | log | |
| Odds ratio, group 1 over group 2 | 0.895 | 0.743 | 1.08 | log | |
| Number needed to treat, for one fewer participant with the outcome on Drug-specific Alert than on Usual Care | 102 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: usual care.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Drug-specific Alert | A drug-specific AKI alert, including information about the drug of interest as well as the presence of AKI will be fired.~Drug-specific alert: A drug-specific alert, informing the provider of the presence of AKI as well as recent exposure to a potentially nephrotoxic agent, will be fired. | 231 | 2,470 | OG001 |
| Group 2 | Usual Care | No alert will be fired. | 256 | 2,478 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Percentage of Patients With AKI Progression From Stage 2 to Stage 3
- Description
- Progression to stage 3 AKI, represented by a tripling of baseline creatinine levels.
- Time frame
- Assessed from date of randomization to date of documented AKI progression, within 14 days of randomization
- Population
- Analyzed population includes subjects with Stage 1 or Stage 2 AKI upon enrollment.
Source ClinicalTrials.gov
Trial
- Title
- Drug-Targeted Alerts for Acute Kidney Injury
- NCT number
- NCT02771977
- Phases
- NA
- Conditions
- Acute Kidney Injury
- Interventions
- Drug-specific alert
- Lead sponsor
- Yale University
- Results first posted
- 2023-06-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02771977?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02771977-e0aa922f